Literature DB >> 7970952

In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics.

K M Coonan1, E L Kaplan.   

Abstract

Because of the recent resurgence of Group A streptococcal infections and their sequelae and to concerns about Group A streptococcal antimicrobial resistance, 282 isolates from acute pharyngitis and 43 additional isolates from severe, invasive infections were examined for susceptibility to 11 oral antibiotics. M serotypes 1, 2, 3, 4 and 12 accounted for more than one-half of the pharyngeal isolates; M serotypes 1 and 3 accounted for most isolates from severe infections. All 325 isolates were exquisitely susceptible to penicillin (Concentration of antibiotic required to inhibit 90% of isolates, 0.012 micrograms/ml). Only approximately 4% of the tested strains demonstrated an erythromycin minimum inhibitory concentration of 0.5 microgram/ml or greater; the new macrolides, azithromycin and clarithromycin, were similar. The cephalosporins varied somewhat in their ability to inhibit Group A streptococci, but all were effective in vitro. No major differences in minimum inhibitory concentrate were observed between strains associated with severe infections and those from uncomplicated upper respiratory tract infections. On the basis of the 325 isolates examined, we conclude that antimicrobial resistance has not been a factor in the recent resurgence of Group A infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7970952     DOI: 10.1097/00006454-199407000-00009

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  30 in total

1.  Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

Authors:  J C De Azavedo; R H Yeung; D J Bast; C L Duncan; S B Borgia; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Presence of mefA and mefE genes in Streptococcus agalactiae.

Authors:  C Arpin; H Daube; F Tessier; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Streptococcal pharyngitis: is penicillin still the drug of choice?

Authors:  K R Rajesh; R C Gordon
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

4.  Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 5.  Antibacterial therapy for acute group a streptococcal pharyngotonsillitis: short-course versus traditional 10-day oral regimens.

Authors:  Itzhak Brook
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Emergence of erythromycin-resistant, clindamycin-susceptible Streptococcus pyogenes isolates in Madrid, Spain.

Authors:  I Garcia-Bermejo; J Cacho; B Orden; J I Alós; J L Gómez-Garcés
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. Pharyngitis Study Group.

Authors:  D Adam; H Scholz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

8.  Prevalence of polyclonal mefA-containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan.

Authors:  J J Yan; H M Wu; A H Huang; H M Fu; C T Lee; J J Wu
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

Review 9.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area.

Authors:  Meredith E Hasenbein; John E Warner; Kathleen G Lambert; Sarah E Cole; Andrew B Onderdonk; Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.